Morgan Stanley Raises Moderna Price Target to $200 From $95, Maintains Equalweight
Morgan Stanley raised its price target on Moderna to $200 from $95 and maintained its Equalweight rating.
Morgan Stanley raised its price target on Moderna to $200 from $95 and maintained its Equalweight rating.